| Bioactivity | IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential. IV-23 inhibits cell growths in vitro and in vivo, reduces colony formation, arrests cell cycle at M phase, and induces esophageal squamous cell carcinoma (ESCC)[1]. |
| Invitro | IV-23 (Compound 20) shows a strong inhibition against the ESCCs in a concentration depend manner, the IC50 values against the Kyse30 and Kyse450 cell lines were all less than 2 μM, presented in a dose-dependent manner. IV-23 triggeres caspases related apoptosis in ESCC cells[1]. IV-23 induces G2/M phase arrest[1]. |
| Name | IV-23 |
| CAS | 2326007-49-0 |
| Formula | C18H18BrNO4 |
| Molar Mass | 392.24 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
IV-23
CAS: 2326007-49-0 F: C18H18BrNO4 W: 392.24
IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.